Evidence map›Paper›PMID 37844099›Full record

ArticlePLoS pathogens2023

SARS-CoV-2 suppresses TLR4-induced immunity by dendritic cells via C-type lectin receptor DC-SIGN.

Lieve E H van der Donk, Marta Bermejo-Jambrina, John L van Hamme, Mette M W Volkers, Ad C van Nuenen, Neeltje A Kootstra, Teunis B H Geijtenbeek

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lieve E H van der DonkDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Marta Bermejo-JambrinaDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
John L van HammeDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Mette M W VolkersDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Ad C van NuenenDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Neeltje A KootstraDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Teunis B H GeijtenbeekDepartment of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5710-2839
Amsterdam University Medical Centers · NLInnsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 causes COVID-19, an infectious disease with symptoms ranging from a mild cold to severe pneumonia, inflammation, and even death. Although strong inflammatory responses are a major factor in causing morbidity and mortality, superinfections with bacteria during severe COVID-19 often cause pneumonia, bacteremia and sepsis. Aberrant immune responses might underlie increased sensitivity to bacteria during COVID-19 but the mechanisms remain unclear. Here we investigated whether SARS-CoV-2 directly suppresses immune responses to bacteria. We studied the functionality of human dendritic cells (DCs) towards a variety of bacterial triggers after exposure to SARS-CoV-2 Spike (S) protein and SARS-CoV-2 primary isolate (hCoV-19/Italy). Notably, pre-exposure of DCs to either SARS-CoV-2 S protein or a SARS-CoV-2 isolate led to reduced type I interferon (IFN) and cytokine responses in response to Toll-like receptor (TLR)4 agonist lipopolysaccharide (LPS), whereas other TLR agonists were not affected. SARS-CoV-2 S protein interacted with the C-type lectin receptor DC-SIGN and, notably, blocking DC-SIGN with antibodies restored type I IFN and cytokine responses to LPS. Moreover, blocking the kinase Raf-1 by a small molecule inhibitor restored immune responses to LPS. These results suggest that SARS-CoV-2 modulates DC function upon TLR4 triggering via DC-SIGN-induced Raf-1 pathway. These data imply that SARS-CoV-2 actively suppresses DC function via DC-SIGN, which might account for the higher mortality rates observed in patients with COVID-19 and bacterial superinfections.

Indexed as

COVID-19SuperinfectionCytokinesDC-Specific ICAM-3 Grabbing NonintegrinDendritic CellsHumansLectins, C-TypeLipopolysaccharidesSARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 4CytokinesDC-Specific ICAM-3 Grabbing NonintegrinLectins, C-TypeLipopolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID37844099
PMCPMC10602378
OpenAlexW4387665951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.